Phase II Trial to Evaluate the Efficacy and Safety of the Combination of Obinutuzumab and Bendamustine Treatment in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Introduction:The use of combined rituximab (R)-bendamustine(B) has shown to be effective in terms of overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) in pts with relapsed/refractory CLL. Based on the enhanced in vitro and in vivo anti-CLL activity of obinutuzumab compared to rituximab, we designed this phase II study to evaluate the efficacy of obinutuzumab(Obi) with B in patients (pts) with relapsed or refractory CLL.